X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BG-68501, a small molecule cyclin-dependent kinase 2 (CDK2) inhibitor, which is being evaluated for the treatment of HR+/HER2 solid tumors including breast, ovarian, and Small Cell Lung Cancer.
Lead Product(s): BG-68501,Fulvestrant
Therapeutic Area: Oncology Product Name: BG-68501
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: BeiGene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2024
Details:
Under the agreement, BeiGene will acquire an exclusive global license to an Investigational New Drug application-ready, ETX-197, an oral cyclin-dependent kinase 2 (CDK2) inhibitor.
Lead Product(s): ETX-197
Therapeutic Area: Oncology Product Name: ETX-197
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: BeiGene
Deal Size: $1,330.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 21, 2023
Details:
Proceeds will be used to further advance the company's Kinetic Ensemble platform and accelerate R&D pipeline. Biomolecules such as proteins and RNAs are in constant motion, with an ensemble of conformations that govern their functions.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: GGV Capital
Deal Size: $67.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
